Phase 3 Trial to Evaluate Efficacy & Safety of Aficamten (CK-3773274) in oHCM (SEQUOIA-HCM)

  • Research type

    Research Study

  • Full title

    A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction



  • Contact name

    Lynsey Kennedy

  • Contact email

  • Sponsor organisation

    Cytokinetics, Inc.

  • Eudract number


  • Identifier


  • Research summary

    The purpose of this study is to determine the effects of CK-3773274 on exercise capacity and general health status of participants with oHCM. The safety and tolerability of CK-3773274 will also be studied.

  • REC name

    East Midlands - Nottingham 2 Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    25 May 2022

  • REC opinion

    Further Information Favourable Opinion

Shape the future of the HRA website.